SCHEMBL11328461

SCHEMBL11328461

COC(=O)c1cn2c(C)c(C)sc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.39
HPGD P15428 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TSHR P16473 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
USP2 O75604 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RAB9A P51151 6/20 0.39
KDM4E B2RXH2 4/20 0.39
NPC1 O15118 3/20 0.39
HTT P42858 2/20 0.39
CYP1A2 P05177 2/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
TP53 P04637 2/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.36
LMNA P02545 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11323481 0.84 GAA (0.52) MAPTHPGDRAB9AKDM4ENPC1
SCHEMBL11314056 0.82 L3MBTL1 (0.40) MAPTHPGDSMN1; SMN2TSHRNPSR1
SCHEMBL17863723 0.81 RAB9A (0.36) MAPTSMN1; SMN2TSHRNPSR1USP2
SCHEMBL11314026 0.81 RAB9A (0.39) MAPTHPGDSMN1; SMN2TSHRUSP2
SCHEMBL17863722 0.81 SMN1; SMN2 (0.36) MAPTHPGDSMN1; SMN2TSHRNPSR1
SCHEMBL11333368 0.79 HPGD (0.48) MAPTHPGDSMN1; SMN2TSHRNPSR1
SCHEMBL11319468 0.74 ALOX15 (0.57) MAPTHPGDSMN1; SMN2TSHRRAB9A
SCHEMBL20518799 0.73 ALDH1A1 (0.52) MAPTSMN1; SMN2TSHRRAB9AKDM4E
SCHEMBL17863721 0.72 CYP19A1 (0.42) MAPTHPGDNPSR1KDM4EMEN1
SCHEMBL11314005 0.70 GAA (0.50) MAPTHPGDRAB9AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4267339-A ANTIDIABETIC AGENTS PLANTEX LTD. (IL) 1981-05-12 US claimed
US-4137320-A Pharmaceutical compositions containing imidazo(2,1-b)thiazoles and process for reducing blood sugar levels therewith PLANTEX, LTD. (IL) 1979-01-30 US claimed
US-9512144-B2 Imidazothiazole sufonamides as nematicides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-12-06 US disclosed
US-20160176898-A1 IMIDAZOTHIAZOLE SUFONAMIDES AS NEMATICIDES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-06-23 US disclosed
US-4267339-A ANTIDIABETIC AGENTS PLANTEX LTD. (IL) 1981-05-12 US disclosed
US-4137320-A Pharmaceutical compositions containing imidazo(2,1-b)thiazoles and process for reducing blood sugar levels therewith PLANTEX, LTD. (IL) 1979-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176898-A1 IMIDAZOTHIAZOLE SUFONAMIDES AS NEMATICIDES NISCH, TST, SULT1E1 MAPT 2089/4885HPGD 1689/4885SMN1; SMN2 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.